2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases

Patent metadata

Field	Value
Publication number	US-11718593-B2
Application number	US-201917053512-A
Country	US
Kind code	B2
Filing date	May 16, 2019
Priority date	May 17, 2018
Publication date	Aug 8, 2023
Grant date	Aug 8, 2023

Abstract

The present disclosure is concerned with 2,5-amino-thiazole compounds that are capable of activating NF-κB signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD), and neuromuscular disorders such as, for example, Duchenne muscular dystrophy (DMD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

First claim

What is claimed is:

1. A compound having a structure represented by a formula:

wherein Ar 1 is selected from monocyclic aryl and pyridinyl, and is substituted with 0, 1, or 2 groups independently selected from halogen, —CN, —NH 2 , —OH, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino,
or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein Ar 1 is monocyclic aryl substituted with 0 additional groups.

3. The compound of claim 1 , wherein the compound is selected from:

or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Assignees

• Southern Res Inst

Inventors

• Suto Mark J
• Mathew Bini
• Cowell Rita
• Augelli-Szafran Corinne E

Classifications

• C07D277/42 Primary

  Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• C07D277/22

  with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms · CPC title

• C07D277/30

  Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title

• C07D317/58

  Radicals substituted by nitrogen atoms (nitro radicals C07D317/52) · CPC title